AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
142 hedge funds and large institutions have $1.21B invested in Aimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 48 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
31% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 29
Holders
142
Holding in Top 10
4
Calls
$14.9M
Puts
$3.37M
Top Buyers
| 1 | +$10.7M | |
| 2 | +$9.24M | |
| 3 | +$6.09M | |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$5.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.69M |
Top Sellers
| 1 | -$35.6M | |
| 2 | -$16.3M | |
| 3 | -$11.3M | |
| 4 |
AC
Aisling Capital
New York
|
-$6.82M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.85M |